Searched for
SIDDHANT KHANDEKAR
French drugmaker Sanofi looks to spin off its consumer business in IndiaThe leading vaccine maker is working with Bank of America on the demerger process, said the people cited above. About 60% of Sanofi India i...- The boom in India's healthcare firms isn’t showing signs of slowingThe pandemic may have pushed several economies and businesses to the brink, but what stood strong at such a crucial period was India pharma...
- Glenmark Life IPO kicks off: Here's what makes analysts bullish on the issueAnalysts are positive on the company's prospects, given that China Plus One strategy by global formulation makers -- to de-risk their procu...
- Glenmark Life Sciences IPO opens today: Should you subscribe?Considering the FY-21 adjusted EPS of Rs 28.69 on post issue basis, the upper price band of Glenmark Life Sciences IPO implies a P/E of 25....
- Stocks that may gain from Covid surgeNow, with the virus making a comeback, companies dealing in oxygen or medical equipment supplies, manufacturers of Covid-19 drugs, vaccine ...
- India’s best-performing stock is seeing a wave of optimistic callsThe optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chine...
- Up in downturn: While the economic slowdown is taking root, manufacturing shows a different storySome sectors like apparel, steel & food production bucked the trend in the manufacturing space.
- Apollo's back on track by doubling its bottom line in FY19Apollo was founded by Prathap Reddy. It's now run by his four daughters — Suneeta, Preetha, Sangita, Shobana.
- Pharma in better health, these five stocks may be a good betAnalysts believe one can look at select stocks in the midcap and largecap pharma space.
- Stocks that can give 20-40% returns from current levelsGlenmark stock has corrected 26% in the past one month due to the poor March quarter results.
- Now open: Narayana Hrudayalaya's IPO likely to cross the line todayNarayana Hrudayalaya's initial public offering (IPO) has received bids for 30% of the issue size so far, data on the National Stock Exchang...
- Narayana Hrudayalaya’s IPO receives tepid response from marketsMerchant bankers believe that the issue will get fully subscribed on Monday with more retail and FII bids coming in at the last minute.
- Aurobindo at a record high, price-to-earnings at 32% discount to peersFor the next fiscal, the stock is trading at 8.7 times to its P/E multiple compared with an average 15.3 times, which is at a 52% discount ...
- Wockhardt continues to slide as street loses faithOn July 18, the US FDA said in a warning letter that the company “repeatedly delayed, denied, limited an inspection or refused to permit th...
- USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term?Manufacturing-related indiscretions of Indian firms put a question mark on prospects for generics exports.
- Glenmark Pharma in $613-million licensing deal with SanofiGlenmark Pharmaceuticals has licensed a new biotech drug to France's Sanofi which has the potential to generate revenues of $613 million or...
- Piramal Health hits 52-wk low, Piramal Life zoomsShares of Piramal Healthcare fell over 12 percent to hit 52-week low as investors gave a thumbs down to its planned financial services fora...
- Pfizer in $200 million insulin deal with BioconBiocon received $200 million upfront from New York-based Pfizerwhich is re-entering the $14-billion global insulin market almost four years...
- Parabolic Drugs debuts marginally up on BSEShares of Parabolic Drugs Ltd debuted on the BSE marginally above its issue price of 75 rupees but later fell more than 12 per cent.
Load More
